ChE Seminar: Dr. Kelvin H. Lee
Event Date: | December 3, 2019 |
---|---|
Speaker: | Dr. Kelvin H. Lee |
Speaker Affiliation: | University of Delaware |
Time: | 3:00-4:15 pm |
Location: | FRNY G140 |
Open To: | Attendance required for PhD students |
Priority: | No |
School or Program: | Chemical Engineering |
College Calendar: | Show |
Dr. Kelvin H. Lee
University of Delaware

Gore Professor of Chemical & Biomolecular Engineering
Institute Director, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
University of Delaware
Part of the Fall 2019 Graduate Seminar Series
A Host Cell Protein Contaminant that May Impact Antibody Drug Product Stability
Abstract:
Chinese hamster ovary (CHO) cells are the preferred platform for biotherapeutic protein production. Monoclonal antibodies (mAbs) alone are predicted to reach global sales of 125 billion USD in 2020 and are used to treat many oncological, immunological and cardiovascular diseases. During the production of therapeutic proteins by CHO cells, host cell proteins (HCPs) are also secreted by the cells. Certain HCPs, if not removed during subsequent purification processes, have been shown to cause immunogenic responses in patients. In this presentation, we will discuss the role of having an accurate, high quality genome, in the identification and characterization of HCPs as well as in the identification and characterization of particularly problematic HCPs that are difficult to remove and can impact product stability. We will also discuss how a large-scale public-private partnership, the National Institute for Innovation in Manufacturing Biopharmaceuticals, brings together Purdue scientists to work with colleagues from government, industry, and academia to tackle biopharmaceutical manufacturing technology innovation.
Bio:
Kelvin H. Lee is Gore Professor of Chemical and Biomolecular Engineering at the University of Delaware and is Director of NIIMBL: the National Institute for Innovation in Manufacturing Biopharmaceuticals, one of 14 Manufacturing USA Institutes. He received a BSE in Chemical Engineering from Princeton and PhD in Chemical Engineering from Caltech. He spent several years in the Biotechnology Institute at the ETH in Zurich, Switzerland and also completed a postdoc in Caltech's Biology Division. Prior to his current appointment, he was on the faculty at Cornell University where he held the titles of: Samuel C. and Nancy M. Fleming Chair Professor, Professor in the School of Chemical and Biomolecular Engineering, Director of the Cornell Institute for Biotechnology, and Director of the New York State Center for Life Science Enterprise.
Learn more about Dr. Kelvin H. Lee at: https://www.che.udel.edu/people/faculty/khl/